Fulcrum Therapeutics, Inc. (FULC)

Over the past six months, Fulcrum Therapeutics has experienced several stock events. On April 27, 2026, the company reported its First Quarter 2026 earnings, showing a net loss of $18.9 million and cash of $333.3 million, with a projected cash runway into 2029. On February 24, 2026, Fulcrum announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial in SCD and plans to initiate a potential registration-enabling trial in the second half of 2026. On December 7, 2025, Fulcrum held a virtual investor event to review new clinical data from the PIONEER trial of pociredir in Sickle Cell Disease. On October 29, 2025, Fulcrum Therapeutics reported its Third Quarter 2025 financial results, announcing encouraging results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in SCD.

The provided information does not indicate any specific demand seasonality for Fulcrum Therapeutics' products or services. Demand for its product candidates is likely driven by medical need rather than seasonal patterns.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases with high unmet medical needs. They operate in the biotechnology and drug discovery industries, utilizing a proprietary product engine to modulate gene expression. Their lead product candidate, pociredir, is in clinical development for sickle cell disease and beta-thalassemia, with positive Phase 1b trial results. The company also has other clinical-stage and pre-clinical programs targeting rare genetic diseases.

Fulcrum Therapeutics is headquartered in Cambridge, Massachusetts, and was incorporated in Delaware.

Fulcrum Therapeutics' brand reputation is tied to its clinical trial progress and financial stability. Positive clinical data from the PIONEER trial for pociredir has been consistently highlighted. The company has engaged in patient-focused collaborations to improve access to care information for individuals with sickle cell disease. However, the stock has experienced negative reactions following some earnings announcements, suggesting a cautious market response.

Fulcrum Therapeutics has significant institutional ownership, with 174 institutional owners and shareholders holding 67,720,414 shares as of May 5, 2026. RA Capital Management LP is the largest individual shareholder, owning 13.05 million shares, representing 19.60% of the company. Institutional investors hold 101.27% of the stock, while Fulcrum Therapeutics insiders hold 43.39%.